clinical-stage biopharmaceutical research

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. It develops first-in-class therapeutic peptides with anti-fibrotic, anti-inflammatory, cell regenerative, and metabolic effects. Its lead drug ALY688ER is an extended release formulation and potent activator of adiponectin signaling pathways; ALY688 is described as the first adiponectin receptor agonist to enter human testing. Lead indication is Duchenne muscular dystrophy.

drug developmenttherapeutic peptide development

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing a first-in-class biologic therapy targeting fundamental drivers of solid tumor progression. Its lead program, BXQ-350, is a novel modulator of sphingolipid metabolism designed to selectively target dysregulated sphingolipids common in tumor cells, with encouraging Phase 1b/2a data in metastatic colorectal cancer.

drug developmentoncology therapeutics

Elion Therapeutics is a clinical-stage biopharmaceutical company in Boston, MA, named for Gertrude Elion. Its mission is to deliver safe and effective therapies to prevent and treat infections in highly vulnerable people, particularly those with cancer and transplant care. The company is backed by $82M in Series B financing from Deerfield, AMRAF, and UI Ventures, and its leadership team has shaped nearly every antifungal on the market today.

clinical studiesdrug design